BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 35059896)

  • 1. SARS-CoV-2 spike protein inhibits growth of prostate cancer: a potential role of the COVID-19 vaccine killing two birds with one stone.
    Johnson BD; Zhu Z; Lequio M; Powers CGD; Bai Q; Xiao H; Fajardo E; Wakefield MR; Fang Y
    Med Oncol; 2022 Jan; 39(3):32. PubMed ID: 35059896
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Role of SARS-CoV-2 Spike Protein in the Growth of Cervical Cancer Cells.
    Willson CM; Lequio M; Zhu Z; Wakefield MR; Bai Q; Fajardo E; Xiao H; Leung S; Fang Y
    Anticancer Res; 2024 May; 44(5):1807-1815. PubMed ID: 38677738
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A single dose of recombinant VSV-∆G-spike vaccine provides protection against SARS-CoV-2 challenge.
    Yahalom-Ronen Y; Tamir H; Melamed S; Politi B; Shifman O; Achdout H; Vitner EB; Israeli O; Milrot E; Stein D; Cohen-Gihon I; Lazar S; Gutman H; Glinert I; Cherry L; Vagima Y; Lazar S; Weiss S; Ben-Shmuel A; Avraham R; Puni R; Lupu E; Bar-David E; Sittner A; Erez N; Zichel R; Mamroud E; Mazor O; Levy H; Laskar O; Yitzhaki S; Shapira SC; Zvi A; Beth-Din A; Paran N; Israely T
    Nat Commun; 2020 Dec; 11(1):6402. PubMed ID: 33328475
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD4
    Taborska P; Strizova Z; Stakheev D; Sojka L; Bartunkova J; Smrz D
    Front Immunol; 2021; 12():629102. PubMed ID: 34012431
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comprehensive characterization of the antibody responses to SARS-CoV-2 Spike protein finds additional vaccine-induced epitopes beyond those for mild infection.
    Garrett ME; Galloway JG; Wolf C; Logue JK; Franko N; Chu HY; Matsen FA; Overbaugh JM
    Elife; 2022 Jan; 11():. PubMed ID: 35072628
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-Resolution Linear Epitope Mapping of the Receptor Binding Domain of SARS-CoV-2 Spike Protein in COVID-19 mRNA Vaccine Recipients.
    Nitahara Y; Nakagama Y; Kaku N; Candray K; Michimuko Y; Tshibangu-Kabamba E; Kaneko A; Yamamoto H; Mizobata Y; Kakeya H; Yasugi M; Kido Y
    Microbiol Spectr; 2021 Dec; 9(3):e0096521. PubMed ID: 34756082
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Response and Duration of Serum Anti-SARS-CoV-2 Antibodies After Inactivated Vaccination Within 160 Days.
    Xu QY; Xue JH; Xiao Y; Jia ZJ; Wu MJ; Liu YY; Li WL; Liang XM; Yang TC
    Front Immunol; 2021; 12():786554. PubMed ID: 35003104
    [TBL] [Abstract][Full Text] [Related]  

  • 8. B and T cell response to SARS-CoV-2 vaccination in health care professionals with and without previous COVID-19.
    Zollner A; Watschinger C; Rössler A; Farcet MR; Penner A; Böhm V; Kiechl SJ; Stampfel G; Hintenberger R; Tilg H; Koch R; Antlanger M; Kreil TR; Kimpel J; Moschen AR
    EBioMedicine; 2021 Aug; 70():103539. PubMed ID: 34391087
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Previous Infection Combined with Vaccination Produces Neutralizing Antibodies with Potency against SARS-CoV-2 Variants.
    Ibarrondo FJ; Hofmann C; Ali A; Ayoub P; Kohn DB; Yang OO
    mBio; 2021 Dec; 12(6):e0265621. PubMed ID: 34872349
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Immune Response to SARS-CoV-2 Vaccination: Insights Learned From Adult Patients With Common Variable Immune Deficiency.
    Quinti I; Locatelli F; Carsetti R
    Front Immunol; 2021; 12():815404. PubMed ID: 35126372
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serological response in health care workers after a single dose of SARS-CoV-2 vaccine using six automated SARS-CoV-2 antibody assays.
    Cuykx M; Mortelé O; Jansens H; Schouwers S; Meskal A; Hoffbauer I; Peeters B
    Diagn Microbiol Infect Dis; 2021 Oct; 101(2):115486. PubMed ID: 34332306
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Possible Role for Anti-idiotype Antibodies in SARS-CoV-2 Infection and Vaccination.
    Murphy WJ; Longo DL
    N Engl J Med; 2022 Jan; 386(4):394-396. PubMed ID: 34818473
    [No Abstract]   [Full Text] [Related]  

  • 13. Neutralizing-antibody-independent SARS-CoV-2 control correlated with intranasal-vaccine-induced CD8
    Ishii H; Nomura T; Yamamoto H; Nishizawa M; Thu Hau TT; Harada S; Seki S; Nakamura-Hoshi M; Okazaki M; Daigen S; Kawana-Tachikawa A; Nagata N; Iwata-Yoshikawa N; Shiwa N; Suzuki T; Park ES; Ken M; Onodera T; Takahashi Y; Kusano K; Shimazaki R; Suzaki Y; Ami Y; Matano T
    Cell Rep Med; 2022 Feb; 3(2):100520. PubMed ID: 35233545
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Peritoneal Administration of a Subunit Vaccine Encapsulated in a Nanodelivery System Not Only Augments Systemic Responses against SARS-CoV-2 but Also Stimulates Responses in the Respiratory Tract.
    Jearanaiwitayakul T; Apichirapokey S; Chawengkirttikul R; Limthongkul J; Seesen M; Jakaew P; Trisiriwanich S; Sapsutthipas S; Sunintaboon P; Ubol S
    Viruses; 2021 Nov; 13(11):. PubMed ID: 34835008
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Boosting of cross-reactive antibodies to endemic coronaviruses by SARS-CoV-2 infection but not vaccination with stabilized spike.
    Crowley AR; Natarajan H; Hederman AP; Bobak CA; Weiner JA; Wieland-Alter W; Lee J; Bloch EM; Tobian AAR; Redd AD; Blankson JN; Wolf D; Goetghebuer T; Marchant A; Connor RI; Wright PF; Ackerman ME
    Elife; 2022 Mar; 11():. PubMed ID: 35289271
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular deconvolution of the neutralizing antibodies induced by an inactivated SARS-CoV-2 virus vaccine.
    Zhou X; Wang H; Ji Q; Du M; Liang Y; Li H; Li F; Shang H; Zhu X; Wang W; Jiang L; Stepanov AV; Ma T; Gong N; Jia X; Gabibov AG; Lou Z; Lu Y; Guo Y; Zhang H; Yang X
    Protein Cell; 2021 Oct; 12(10):818-823. PubMed ID: 33909239
    [No Abstract]   [Full Text] [Related]  

  • 17. Spike Antibody Titers Evaluation after a 2-Dose Regimen of BNT162b2 Vaccination in Healthcare Workers Previously Infected with SARS-CoV-2.
    Kayukawa S; Nanya K; Morita M; Ina K; Ota Y; Hasegawa S
    Microbiol Spectr; 2021 Dec; 9(3):e0103621. PubMed ID: 34756062
    [No Abstract]   [Full Text] [Related]  

  • 18. Evaluation of the SARS-CoV-2 Antibody Response to the BNT162b2 Vaccine in Patients Undergoing Hemodialysis.
    Yau K; Abe KT; Naimark D; Oliver MJ; Perl J; Leis JA; Bolotin S; Tran V; Mullin SI; Shadowitz E; Gonzalez A; Sukovic T; Garnham-Takaoka J; de Launay KQ; Takaoka A; Straus SE; McGeer AJ; Chan CT; Colwill K; Gingras AC; Hladunewich MA
    JAMA Netw Open; 2021 Sep; 4(9):e2123622. PubMed ID: 34473256
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimization of SARS-CoV-2 Spike Protein Expression in the Silkworm and Induction of Efficient Protective Immunity by Inoculation With Alum Adjuvants.
    Masuda A; Lee JM; Miyata T; Mon H; Sato K; Oyama K; Sakurai Y; Yasuda J; Takahashi D; Ueda T; Kato Y; Nishida M; Karasaki N; Kakino K; Ebihara T; Nagasato T; Hino M; Nakashima A; Suzuki K; Tonooka Y; Tanaka M; Moriyama T; Nakatake H; Fujita R; Kusakabe T
    Front Immunol; 2021; 12():803647. PubMed ID: 35095889
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum antibody response in patients with philadelphia-chromosome positive or negative myeloproliferative neoplasms following vaccination with SARS-CoV-2 spike protein messenger RNA (mRNA) vaccines.
    Kozak KE; Ouyang L; Derkach A; Sherman A; McCall SJ; Famulare C; Chervin J; Daley RJ; Morjaria S; Mauro MJ; Rampal RK
    Leukemia; 2021 Dec; 35(12):3578-3580. PubMed ID: 34741117
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.